Autorisation d’accès précoce refusée à la spécialité QALSODY (tofersen) dans l’indication « traitement des adultes atteints de sclérose latérale amyotrophique (SLA) associée à une mutation du gène superoxyde dismutase 1 (SOD1) ».
See also
HAS opinions and decisions
22/10/2024
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
QeEXXQpkrgnhneXU
Listen
